Junhem Biopharma Secures Nearly RMB 100 Million in Series A+ Financing Within Three Months, WinX Capital Continues as Exclusive Financial Advisor

Recently,JHM Biopharmaceutical (Hangzhou) Co., Ltd. (hereinafter referred to as “JHM Biopharma”) has completed an A+ round of financing amounting to nearly RMB 100 million. This round was jointly invested by Bencao Capital and Guangdian Capital, with Kaicheng Capital continuing to serve as the exclusive financial advisor.The proceeds from this round of financing will be primarily used to further advance the development of the company’s product pipeline in clinical trials, expand its pipeline reserves, and construct GMP-compliant commercial manufacturing facilities.

Following the completion of its nearly RMB 200 million Series A financing last October (see link to previous press release), JHM Biopharma has secured another capital injection of nearly RMB 100 million just three months later. Amidst a tightening macroeconomic environment and a cooling capital market, JHM Biopharma’s ability to break through the constraints and complete two rounds of financing in quick succession fully demonstrates the capital market’s strong recognition of the company’s team and technology.

JHM Biopharma, established in November 2020, is an international innovative enterprise focused on cutting-edge protein therapeutics for broad markets. Leveraging the core team’s over 20 years of experience in the R&D and industrialization of protein drugs, JHM Biopharma has built a recombinant protein drug development platform that balances druggability with innovation. This platform encompasses high-efficiency expression systems for recombinant proteins, proprietary micro-denaturation separation and purification technologies, in vitro protein folding and self-assembly systems, and long-acting sustained-release technologies—high-barrier capabilities that have already achieved industrial application. Furthermore, the company’s executive team has worked together for more than a decade, jointly developing multiple protein therapeutics from project initiation, R&D, manufacturing, and clinical trials to commercial launch. The team’s high stability, strong collaboration, and cohesion safeguard the company’s long-term development. Notably, JHM Biopharma has constructed a nearly 8,000-square-meter GMP production facility at Hangzhou Medical Port, which is capable of meeting the production and commercialization needs of its product pipeline, making it one of the few biotech companies with proven industrialization experience.

JHM Biopharma’s R&D pipeline is strategically focused on frontier protein therapeutics in broad markets such as metabolism and medical aesthetics, with its lead products centered on recombinant protein drugs possessing consumer attributes, including recombinant botulinum toxin type A and growth hormone. Following the completion of this financing round, JHM Biopharma will continue to dedicate itself to the in-depth research of foundational technologies for recombinant protein drugs, build a constantly enriching and iteratively evolving product pipeline aligned with market demands, and accelerate clinical development to benefit patients and consumers at the earliest possible time.

JHM Biopharma CEO Xu KuiStatement: We sincerely appreciate the investors’ recognition and support of the Company, as well as Kaicheng Capital’s continued partnership and its team’s professional and efficient services, which facilitated the rapid completion of this financing round. In light of the substantial market demand in the consumer healthcare sector, we remain committed to foundational platform technology innovation and continuous product iteration and upgrading, with a strategic focus on recombinant protein drugs featuring independent intellectual property rights. We are confident that, through the joint efforts of our team and institutional investors, the Company will emerge as a leading player in the field of recombinant protein therapeutics.

Sun Lue, Investment Director at Bencao CapitalStatement: Amid the rapid growth of the non-surgical medical aesthetics market and the widespread price reductions resulting from centralized procurement of biological drugs, the JHM Biopharma team has leveraged its nearly 20 years of profound expertise in recombinant protein drug development and manufacturing processes, along with its industry-leading execution capabilities. In a short period, the team has overcome technical and cost challenges across multiple pipelines, including recombinant botulinum toxin and recombinant human growth hormone, thereby establishing a robust barrier of independent intellectual property rights and patents. We are honored to participate in the company’s development and believe that, driven by the team’s exceptional R&D and execution capabilities, JHM Biopharma will continue to deliver more products with international competitiveness in the field of recombinant protein therapeutics.

Cai Ning, Managing Partner at Guangdian CapitalGuangdian Capital stated that it remains bullish on the immense potential of the Company’s next-generation recombinant botulinum toxin type A, growth hormone, and other products in the future medical aesthetics and metabolic consumer healthcare markets. Guangdian Capital has consistently monitored the Company’s growth and witnessed the professionalism and proactive spirit of its team. Believing that the Company will achieve further breakthroughs in the field of recombinant protein therapeutics, Guangdian Capital is pleased to continue investing in JHM Biopharma alongside existing and new shareholders. It aims to support and empower the enterprise from multiple dimensions, facilitating its development into an internationally renowned company in the recombinant protein therapeutics sector.

Dr. Zou Guowen, Founding Partner of Kaicheng CapitalStatement: Kaicheng Capital is honored to serve as the long-term capital partner of JHM Biopharma and to continue leading its subsequent financing rounds. We extend our sincere gratitude to the company and its institutional investors for their trust in Kaicheng Capital. As an active participant in the high-growth consumer healthcare sector, JHM Biopharma boasts industry-leading innovative platform technologies, robust product iteration capabilities, and extensive industrialization experience. Backed by a seasoned R&D and management team with a global perspective, the company has developed a pipeline of products that meet substantial market demand, emerging as a standout dark horse in China’s—and indeed the global—consumer healthcare landscape. We are confident that, with the support of its shareholders, JHM Biopharma will usher in a new chapter for China’s consumer healthcare industry.

Bencao Capital is a specialized investment fund dedicated to investing in globally leading life sciences and healthcare companies, with a focus on two key areas: innovative pharmaceuticals, and cross-disciplinary innovative medical devices and diagnostic technologies. The core founding team members all hold PhDs in biomedical fields from overseas institutions, bringing years of practical experience in the pharmaceutical and biotech industries, as well as over a decade of successful investment and entrepreneurial experience both in China and abroad. This combination equips them with strong professional expertise, deep industry insight, and an international perspective. As a dual-currency fund manager operating in both RMB and USD, Bencao Capital has cumulatively invested in and incubated more than 90 innovative healthcare enterprises domestically and internationally, with offices in Beijing, Shanghai, and Silicon Valley. Upholding its vision of “empowering great healthcare companies and building an internationally recognized professional investment brand,” Bencao Capital provides strategic support to outstanding entrepreneurial teams while delivering superior returns to its investors.

Founded in 2016, Guangdian Capital is one of China’s most dynamic private equity investment firms, focusing on growth-stage enterprises in the consumer technology sector. Adhering to the investment strategy of “focusing on industry champions and pursuing long-term value,” Guangdian Capital has identified and connected a cohort of leading companies in vertical sectors. Together with the new generation of entrepreneurs within the Guangdian ecosystem, they have co-created a vibrant new landscape for China’s consumer market. Investment portfolio includes: VSPN Quantum Sports, Taiyang Chuanhe, ACG International Art Education, Jijia Pets, Yiyi Shares, Xiaopi, RedDog, and JinDuoduo, among others.

WinX Capital is a leading investment bank in China’s healthcare sector. Headquartered in Beijing and Shanghai, it serves over 3,000 active institutional investors and industrial groups. From 2020 to 2022, WinX Capital was consecutively recognized by Qimingpian & Xinsheng Chuangfu as “Top 2 Best Financial Advisors in Healthcare (2021–2022),” “Top 4 Best Financial Advisory Firms in Healthcare (2020),” “Top 10 Most Active Financial Advisors (2021),” “Top 6 Comprehensive Financial Advisors (Mid-2022),” and “Top 7 Most Active Financial Advisors (Mid-2022).” It was also listed among the “Top 5 Most Promising New-Type Investment Banks in China (WISE 2020/2021)” by 36Kr and ranked “Top 5 Healthcare Financial Advisors of the Year” at VCBeat’s 2022 “Pengcheng Awards.”